A new combination of Factor Xa inhibition and standard antiplatelet therapy to prevent more recurrent cardiovascular events after ACS

With an unrestricted educational grant from BAYER HEALTHCARE PHARMACEUTICALS

Learning Objectives

  • To understand the dual pathway approach in arterial thrombus formation and the role of thrombin in platelet activation and aggretation, and in the coagulation cascade
  • To comprehend the increased thrombin generation after ACS and the rationale for oral antiplatelet and anticoagulant therapy to reduce residual atherothrombotic risk for patients following ACS
  • To assess how the use of oral anticoagulation may change current standards of care in patients experiencing ACS with elevated cardiac biomarker

Presentations available when logged in:

  • Introduction and objectives
  • Thrombin generation and its critical long-term role post ACS - Combining Rivaroxaban 2.5mg BID and standard antiplatelet therapy to reduce atheroth...
  • Case presentations - Complex NSTE-ACS case and STEMI ACS case: management of patients at high ischaemic risk and low bleeding risk
  • Rivaroxaban clinical trial programme: proven experience and new clinical activities in cardiology
  • Take-home message